Roche Holding and ImmunoGen's Kadcyla was endorsed for approval by the European Medicine Agency's Committee for Medicinal Products for Human Use as a therapy for HER2-positive breast cancer when patients have previously been treated with taxane-based chemotherapy and Herceptin. The drug, which contains Herceptin's monoclonal antibody and ImmunoGen's DM1 cytotoxic agent, was approved in Japan.

Full Story:
PMLive.com (U.K.)

Related Summaries